Presentation on the use of dsuvia® for plastic surgery procedures selected for "best papers" session at the california society of plastic surgeons annual meeting

Hayward, calif., may 26, 2021 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an upcoming podium presentation on dsuvia (sufentanil sublingual tablet 30 mcg) which was selected for the best papers of the regional societies session at the california society of plastic surgeons 71st annual meeting in monterey ca.
ACRX Ratings Summary
ACRX Quant Ranking